Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Gross Profit: 2020-2025

Historic Gross Profit for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $63.4 million.

  • Xeris Biopharma Holdings' Gross Profit rose 55.83% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.0 million, marking a year-over-year increase of 47.63%. This contributed to the annual value of $166.2 million for FY2024, which is 22.89% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Gross Profit stood at $63.4 million, which was up 6.28% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Gross Profit ranged from a high of $63.4 million in Q3 2025 and a low of $5.5 million during Q2 2021.
  • Its 3-year average for Gross Profit is $43.3 million, with a median of $40.3 million in 2024.
  • Data for Xeris Biopharma Holdings' Gross Profit shows a peak YoY spiked of 321.08% (in 2021) over the last 5 years.
  • Xeris Biopharma Holdings' Gross Profit (Quarterly) stood at $16.5 million in 2021, then soared by 62.35% to $26.9 million in 2022, then spiked by 37.12% to $36.8 million in 2023, then soared by 37.48% to $50.6 million in 2024, then spiked by 55.83% to $63.4 million in 2025.
  • Its Gross Profit was $63.4 million in Q3 2025, compared to $59.6 million in Q2 2025 and $51.4 million in Q1 2025.